5 results about "Locally advanced" patented technology

The present disclosure relates to novel radiation-triggered controlled release drug compositions, and methods to make and use the radiation-triggered controlled release drug compositions. The radiation-triggered controlled drug release nanoparticle formulations may be used to achieve maximum bioavailability and minimum adverse effects of the chemo drugs in chemo radio combination therapy treatment of locally advanced solid tumors.

The present application relates to treating and / or preventing breast cancer, including locally advanced or metastatic, ER+, HER2- breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), N n R2 N N O HO ON R R4 NH O (R1) m (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R¹, R², R3, R4, m, and n are defined herein. 20 26 20 54 21 08 J ul 2 02 6 0 8 J u l 2 0 2 6 A B S T R A C T 2 0 2 6 2 0 5 4 2 1 N n N N O H O O N R R 4 N H O m

Provided are combination therapies comprising inavolisib and a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for the treatment of HER2-positive cancers; and methods of treating a PIK3CA mutated, HER2 positive (HER2+) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib and PH FDC SC.

This invention discloses a method and system for constructing an intelligent quality control platform for radiotherapy based on multimodal data, belonging to the field of intelligent quality control technology for radiotherapy. The method includes: collaborating with at least two cross-regional medical centers to collect multimodal data from patients with locally advanced rectal cancer; performing multi-expert annotation on the target area and organs at risk on the CT images according to unified annotation standards; generating consensus annotations using a multi-annotation fusion algorithm; and forming a multi-center standardized dataset after standardization processing. It also involves the parallel construction of an automatic segmentation model, an automatic quality control module for radiotherapy planning, and a multimodal risk stratification model; integrating the automatic segmentation model, automatic quality control module, and risk stratification model into a Web-based platform; and interacting with the radiotherapy information system and radiotherapy planning system through an interface adaptation layer. This provides precise support for promoting the homogenization of radiotherapy quality and the implementation of precision radiotherapy.

A combination therapy comprising enoxacin, palbociclib, and fulvestrant is provided, along with a method for treating locally advanced or metastatic breast cancer with PIC3CA mutations, hormone receptor-positive (HR+), and HER2-negative (HER2-), the method comprising administering therapeutically effective amounts of enoxacin, palbociclib, and fulvestrant. The combination therapy produced statistically significant and clinically meaningful improvements in comparable patients compared to administration of palbociclib and fulvestrant alone.